XORTX Therapeutics (ANU) Stock Overview
A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ANU Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.76 |
| 52 Week High | CA$4.10 |
| 52 Week Low | CA$1.25 |
| Beta | 0.17 |
| 1 Month Change | -6.67% |
| 3 Month Change | -29.52% |
| 1 Year Change | -47.56% |
| 3 Year Change | -92.63% |
| 5 Year Change | -97.47% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANU | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.4% | 0.1% | 2.0% |
| 1Y | -47.6% | 47.3% | 1.2% |
Return vs Industry: ANU underperformed the German Pharmaceuticals industry which returned 51.8% over the past year.
Return vs Market: ANU underperformed the German Market which returned 2.9% over the past year.
Price Volatility
| ANU volatility | |
|---|---|
| ANU Average Weekly Movement | 22.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: ANU's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ANU's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
XORTX Therapeutics Inc. Fundamentals Summary
| ANU fundamental statistics | |
|---|---|
| Market cap | €3.12m |
| Earnings (TTM) | -€2.42m |
| Revenue (TTM) | n/a |
Is ANU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANU income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.77m |
| Earnings | -US$2.77m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 09:37 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
XORTX Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |